ResearcherUniversity of CopenhagenNo recent work listed
Jessica Xin Hjaltelin
Matched on ORCID iD 0000-0002-7878-7830; OpenAlex author ID A5045701610. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 15
2022: 1 paper · 2023: 3 papers
Papers 4
- A deep learning algorithm to predict risk of pancreatic cancer from disease trajectories. Co-author DOI 10.1038/s41591-023-02332-5↗
- Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherap… Co-author DOI 10.3389/fimmu.2023.1228907↗
- Pancreatic cancer symptom trajectories from Danish registry data and free text in electronic health records. Co-author DOI 10.7554/elife.84919↗
- Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (Che… Co-author DOI 10.1200/jco.21.02511↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Søren Brunak · 4 shared papers, 2022–2023 · strength 0.62
- Paper Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint in… DOI 10.3389/fimmu.2023.1228907↗
- Paper Pancreatic cancer symptom trajectories from Danish registry data and free text in electronic health records. DOI 10.7554/elife.84919↗
- Paper A deep learning algorithm to predict risk of pancreatic cancer from disease trajectories. DOI 10.1038/s41591-023-02332-5↗
- Inna Markovna Chen · 3 shared papers, 2022–2023 · strength 0.49
- Paper Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint in… DOI 10.3389/fimmu.2023.1228907↗
- Paper Pancreatic cancer symptom trajectories from Danish registry data and free text in electronic health records. DOI 10.7554/elife.84919↗
- Paper Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refr… DOI 10.1200/jco.21.02511↗
- Susann Theile · 2 shared papers, 2022–2023 · strength 0.31
- Paper Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint in… DOI 10.3389/fimmu.2023.1228907↗
- Paper Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refr… DOI 10.1200/jco.21.02511↗
- Dorte Lisbet Nielsen · 2 shared papers, 2022–2023 · strength 0.31
- Paper Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint in… DOI 10.3389/fimmu.2023.1228907↗
- Paper Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refr… DOI 10.1200/jco.21.02511↗
- Julia Sidenius Johansen · 2 shared papers, 2022–2023 · strength 0.30
- Astrid Zedlitz Johansen · 1 shared paper, 2023 · strength 0.18
- Chen Yuan · 1 shared paper, 2023 · strength 0.13
- Michael Hayden Rosenthal · 1 shared paper, 2023 · strength 0.13
- Jihye Kim · 1 shared paper, 2023 · strength 0.13
- Davide Placido · 1 shared paper, 2023 · strength 0.13
- Chunlei Zheng · 1 shared paper, 2023 · strength 0.13
- Aviv Regev · 1 shared paper, 2023 · strength 0.13
- Peter Kraft · 1 shared paper, 2023 · strength 0.13
- Brian Matthew Wolpin · 1 shared paper, 2023 · strength 0.13
- Chris Sander · 1 shared paper, 2023 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.